Jordan - engelsk - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - digoxin 0.05 mg/ml - 0.05 mg/ml

Jordan - engelsk - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - digoxin 0.25 mg - 0.25 mg

Jordan - engelsk - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - digoxin 0.125 mg - 0.125 mg

USA - engelsk - NLM (National Library of Medicine)

covis pharmaceuticals, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.125 mg

USA - engelsk - NLM (National Library of Medicine)

covis pharmaceuticals, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 250 ug in 1 ml

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pco manufacturing - calcium phosphate, colecalciferol - powder for oral suspension - 1200mg/800 international unit - calcium, combinations with other drugs

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.0625 mg - tablet - excipient ingredients: indigo carmine; lactose monohydrate; magnesium stearate; maize starch; povidone; rice starch; oxidised maize starch

USA - engelsk - NLM (National Library of Medicine)

ajanta pharma usa inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - omeprazole 20 mg - omeprazole and sodium bicarbonate for oral suspension is indicated in adults for the: - short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. - short-term treatment (4 to 8 weeks) of active benign gastric ulcer. - treatment of heartburn and other symptoms associated with gerd for up to 4 weeks. - short-term treatment (4 to 8 weeks) of ee due to acid-mediated gerd which has been diagnosed by endoscopy in adults. the efficacy of omeprazole and sodium bicarbonate for oral suspension used for longer than 8 weeks in patients with ee has not been established. if a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. if there is recurrence of ee or gerd symptoms (e.g., heartburn), additional 4 to 8-week courses of omeprazole and sodium bicarbonate for oral suspension may be considered. - the efficacy of omeprazole and sodium bicarbonate for oral suspension used for longer than 8

USA - engelsk - NLM (National Library of Medicine)

cardinal health 107, llc - dronedarone (unii: jqz1l091y2) (dronedarone - unii:jqz1l091y2) - dronedarone 400 mg - multaq® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (af) [see clinical studies (14)]. multaq is contraindicated in patients with: pregnancy category x [see contraindications (4)] multaq may cause fetal harm when administered to a pregnant woman. in animal studies, dronedarone was teratogenic in rats at the maximum recommended human dose (mrhd), and in rabbits at half the mrhd. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. when pregnant rats received dronedarone at oral doses greater than or equal to the mrhd (on a mg/m2 basis), fetuses had increased rates of external, visceral and skeletal malformations (cranioschisis, cleft palate, incomplete evagination of pineal body, brachygnathia, partially fused carotid arteries, truncus arteriosus, abnormal lobation of the liver,

USA - engelsk - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - protonix for delayed-release oral suspension and protonix delayed-release tablets are indicated for: protonix is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of protonix may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. protonix is indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. protonix is indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison (ze) syndrome. risk summary available data from published observational studies did not demonstrate an association of major malformations or other adverse pregnancy outcomes with pa